Nonpharmacological/Alternative Treatment Options

Download PDF

Learn more about Nonpharmacological/Alternative Treatment Options.
  1. Brain Stimulation Therapies. 2023 [cited 2023/09/14]. 2023.
  2. Dey J, Ahmad H, Hamirani F, Mann SK, Malhi N, Marwaha R. 10.2 CAN MAGNETS CURE DEPRESSION?: A SYSTEMATIC REVIEW OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION FOR ADOLESCENT DEPRESSION. J Am Acad Child & Adolesc Psychiatry. 2020 Oct;59(10):S176. Elsevier BV; 2020 Oct. DOI: 10.1016/j.jaac.2020.08.149.
  3. Transcranial magnetic stimulation. 2023 [cited 2023 Sep 12]. https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625; 2023.
  4. Koponen LM, Goetz SM, Tucci DL, Peterchev AV. Sound comparison of seven TMS coils at matched stimulation strength. Brain Stimul. 2020 May;13(3):873-880. Elsevier BV; 2020 May. DOI: 10.1016/j.brs.2020.03.004.
  5. Gersner R, Barnea-Ygael N, Tendler A. Moderators of the response to deep TMS for smoking addiction. Front Psychiatry. 2023 Jan 9;13. Frontiers Media SA; 2023 Jan 9. DOI: 10.3389/fpsyt.2022.1079138.
  6. Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. AJP. 2019 Nov 1;176(11):931-938. American Psychiatric Association Publishing; 2019 Nov 1. DOI: 10.1176/appi.ajp.2019.18101180.
  7. Stultz DJ, Osburn S, Burns T, Pawlowska-Wajswol S, Walton R. <p>Transcranial Magnetic Stimulation (TMS) Safety with Respect to Seizures: A Literature Review</p>. NDT. 2020 Dec;Volume 16:2989-3000. Informa UK Limited; 2020 Dec. DOI: 10.2147/ndt.s276635.
  8. Cohen SL, Bikson M, Badran BW, George MS. A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices. Brain Stimul. 2022 Jan;15(1):73-75. Elsevier BV; 2022 Jan. DOI: 10.1016/j.brs.2021.11.010.
  9. Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder.
  10. Salik E, Donat A, Ağaoğlu MH. Chiropractic Nimmo Receptor-Tonus Technique and McKenzie Self-Therapy Program in the Management of Adjacent Segment Disease: A Case Report. J Chiropr Medicine. 2020 Dec;19(4):249-259. Elsevier BV; 2020 Dec. DOI: 10.1016/j.jcm.2020.01.002.
  11. Raising Children to Resist Violence: What You Can Do. PsycEXTRA Dataset. 1996. Unmaintained records; 1996. DOI: 10.1037/e301132004-001.
  12. Bassa A, Sagués T, Porta-Casteràs D, Serra P, Martínez-Amorós E, Palao D, et al. The Neurobiological Basis of Cognitive Side Effects of Electroconvulsive Therapy: A Systematic Review. Brain Sci. 2021 Sep 26;11(10):1273. MDPI AG; 2021 Sep 26. DOI: 10.3390/brainsci11101273.
  13. JAFFE R. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed.. AJP. 2002 Feb 1;159(2):331-331. American Psychiatric Association Publishing; 2002 Feb 1. DOI: 10.1176/appi.ajp.159.2.331.
  14. Electroconvulsive Therapy Review Guidelines. 2003 Jan 3 [cited 2023 Sep 16]. 2003 Jan 3.
  15. Anderson IM, McAllister-Williams RH, Downey D, Elliott R, Loo C. Cognitive function after electroconvulsive therapy for depression: relationship to clinical response. Psychol Med. 2021 Jul;51(10):1647-1656. Cambridge University Press (CUP); 2021 Jul. DOI: 10.1017/s0033291720000379.
  16. Food and Drug Administration, HHS. Neurological Devices; Reclassification of Electroconvulsive Therapy Devices; Effective Date of Requirement for Premarket Approval for Electroconvulsive Therapy Devices for Certain Specified Intended Uses. Final order.. Fed Regist. 2018 Dec 26;83(246):66103-24. 2018 Dec 26. PubMed PMID: 30596410.
  17. Emotional Freedom Technique (EFT). Kaiser Permanente. 2023 Jun 25 [cited 2023 Sep 14]. 2023 Jun 25.
  18. Blacher S. Emotional Freedom Technique (EFT): Tap to relieve stress and burnout. J Interprofessional Educ & Pract. 2023 Mar;30:100599. Elsevier BV; 2023 Mar. DOI: 10.1016/j.xjep.2023.100599.
  19. Church D, House D. Borrowing Benefits: Group Treatment With Clinical Emotional Freedom Techniques Is Associated With Simultaneous Reductions in Posttraumatic Stress Disorder, Anxiety, and Depression Symptoms. J Evid Based Complementary Altern Med. 2018 Jan 1;23. SAGE Publications; 2018 Jan 1. DOI: 10.1177/2156587218756510.
  20. Church D. 26.2 An RCT and a Follow-up RCT: Epigenetic Effects of PTSD Remediation Using Clinical Emotional Freedom Therapy (EFT), and an RCT on the Effect of EFT on Stress Biochemistry. J Am Acad Child & Adolesc Psychiatry. 2022 Oct;61(10):S317. Elsevier BV; 2022 Oct. DOI: 10.1016/j.jaac.2022.07.705.
  21. Dincer B, Inangil D. The effect of Emotional Freedom Techniques on nurses' stress, anxiety, and burnout levels during the COVID-19 pandemic: A randomized controlled trial. EXPLORE. 2021 Mar;17(2):109-114. Elsevier BV; 2021 Mar. DOI: 10.1016/j.explore.2020.11.012.
  22. Bach D, Groesbeck G, Stapleton P, Sims R, Blickheuser K, Church D. Clinical EFT (Emotional Freedom Techniques) Improves Multiple Physiological Markers of Health. J Evid Based Complementary Altern Med. 2019 Jan 1;24. SAGE Publications; 2019 Jan 1. DOI: 10.1177/2515690x18823691.
  23. SPRAVATO [package insert]. 2019 [cited 2023/09/17]. Janssen Pharmaceuticals, Inc.; 2019.
  24. Esketamine. Wolters Kluwer Health, Inc. [cited 2023 Sep 23]. Wolters Kluwer Health, Inc..
  25. Updated August 2023 [cited September 23, 2023]. Updated August 2023.
  26. Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry. 2019 Sep 1;76(9):893. American Medical Association (AMA); 2019 Sep 1. DOI: 10.1001/jamapsychiatry.2019.1189.
  27. Wang SM, Kim NY, Na HR, Lim HK, Woo YS, Pae CU, et al. Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. Clin Psychopharmacol Neurosci. 2021 May 31;19(2):341-354. Korean College of Neuropsychopharmacology; 2021 May 31. DOI: 10.9758/cpn.2021.19.2.341.